News
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm’s CXCR4 Core Compound Subject of 17 Abstract Presentations at the Hamburg European Association of Nuclear Medicine (EANM)
Pentixapharm presents CXCR4 targeting compounds in 17 abstracts at EANM Congress, showcasing theranostic developments and research initiatives in various medical areas -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor
EMA grants PRIME status to Pentixapharm’s lead candidate Ga68-PentixaFor, offering early and proactive support for radiodiagnostic development in primary aldosteronism. PentixaFor aims to transform diagnostic subtyping with non-invasive PET imaging targeting CXCR4 -
-
-
-
-
